Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) EPS (Basic) (2020 - 2023)

Cullinan Therapeutics has reported EPS (Basic) over the past 4 years, most recently at -$0.54 for Q4 2023.

  • Quarterly results put EPS (Basic) at -$0.54 for Q4 2023, up 11.48% from a year ago — trailing twelve months through Dec 2023 was -$3.69 (down 248.79% YoY), and the annual figure for FY2025 was -$33.57, down 1107.55%.
  • EPS (Basic) for Q4 2023 was -$0.54 at Cullinan Therapeutics, up from -$0.91 in the prior quarter.
  • Over the last five years, EPS (Basic) for CGEM hit a ceiling of $3.9 in Q2 2022 and a floor of -$1.42 in Q1 2023.
  • Median EPS (Basic) over the past 4 years was -$0.52 (2020), compared with a mean of -$0.33.
  • Peak annual rise in EPS (Basic) hit 1183.33% in 2022, while the deepest fall reached 898.72% in 2022.
  • Cullinan Therapeutics' EPS (Basic) stood at -$1.39 in 2020, then soared by 45.32% to -$0.76 in 2021, then increased by 19.74% to -$0.61 in 2022, then grew by 11.48% to -$0.54 in 2023.
  • The last three reported values for EPS (Basic) were -$0.54 (Q4 2023), -$0.91 (Q3 2023), and -$0.82 (Q2 2023) per Business Quant data.